Concourse Financial Group Securities, Inc. Passage Bio, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$0.64 - $1.0 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$0.79 - $1.58 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.86 - $1.73 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.6 - $1.01 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.66 - $1.01 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.66 - $1.01 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.82 - $1.19 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.96 - $1.88 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.06 - $1.48 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.22 - $2.48 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.63 - $3.46 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.66 - $6.49 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$6.24 - $10.2 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$9.73 - $15.52 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$12.44 - $19.45 $0 - $0
Q1 2021 May 13, 2021	BUY	$16.24 - $29.83 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$14.28 - $29.73 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$12.39 - $26.15 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$14.59 - $36.07 $0 - $0
Q1 2020 May 13, 2020	BUY	$8.86 - $22.2 $0 - $0

Others Institutions Holding PASG

# of Institutions

Shares Held

38.7M

Call Options Held

7.7K

Put Options Held

Orbimed Advisors LLC San Diego, CA

9.82M
Shares

$6.48 Million
0.16% of portfolio
Lynx1 Capital Management LP San Juan, PR

8.43M
Shares

$5.56 Million
2.11% of portfolio
Vestal Point Capital, LP New York, NY

6.1M
Shares

$4.03 Million
0.32% of portfolio
New Leaf Venture Partners, L.L.C. New York, NY

2.5M
Shares

$1.65 Million
1.8% of portfolio
Erste Asset Management Gmb H Vienna, C4

2.46M
Shares

$1.62 Million
0.02% of portfolio

View Full List

About Passage BIO, Inc.

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

More about PASG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account